Evidence map›Paper›PMID 41729325›Full record

Trial reportLasers in medical science2026

The efficacy and safety of 1470 nm diode laser in the treatment of benign prostatic hyperplasia: a prospective, multicenter study.

Hao Xu, Wenbo Kuang, Dongxu Lin, Kang Li, Yang Luan, Kai Cui, Ting Yang, Zhong Chen

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hao Xu *Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wenbo Kuang *Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dongxu LinDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kang LiDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yang LuanDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kai CuiDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ting YangDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. mika101@126.com.
Zhong ChenDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. chenzhongtj@126.com.

Funding

Medical Innovation and Transformation Incubation Project of Tongji Hospital 2022ZHFY11National Natural Science Foundation of China 82270812National Natural Science Foundation of China 823B2013
6 · The paper itself

Abstract

purposeBenign prostatic hyperplasia (BPH) is common in elderly men, causing lower urinary tract symptoms (LUTSs). The 1470 nm diode laser, with high vaporization efficiency and good hemostasis, is increasingly used for BPH. This study sought to comprehensively evaluate the efficacy and safety of 1470 nm diode laser enucleation of the prostate (DiLEP) forBPH in a prospective, multicenter study.

methodsConducted at two hospitals, BPH patients were randomized into two groups. Group A used a new 1470 nm diode laser device (Hefei Han's Kereida), and Group B utilized a conventional and widely validated 1470 nm laser system (Wuhan Qizhi). Prostate volume (PV), maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and Quality of Life (QoL) score were measured pre- and post-operatively. Perioperative indices and complications were also recorded.

results143 patients (73 in Group A, 70 in Group B) completed follow-up. Baseline characteristics of two groups were comparable. Vital parameters remained within normal ranges following the surgical procedure. Both groups showed significant improvements in IPSS, QoL, Qmax, and PVR post-operatively, with no significant differences between groups. Complications occurred in 17 patients in Group A and 10 in Group B, all of which resolved spontaneously or were effectively managed with appropriate interventions.

conclusion1470 nm DiLEP is an effective and safe BPH treatment, relieving symptoms with few complications. The new device from Hefei Han's Kereida performed reliably. This laser offers a valuable alternative to BPH surgeries.

Indexed as

Lasers, SemiconductorLaser TherapyProstatic HyperplasiaAgedHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment Outcome1470 nm diode laserBenign prostatic hyperplasiaEfficacyLaser enucleationSafety

Identifiers

PMID41729325
PMCPMC12929312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.